




I'm not robot



Continue

Jury duty questionnaire hawaii

Investor's Business DailyDow Jones Futures: As the stock market rally stops near the highs, Apple stands out, while Microsoft forms. Taiwan Semi and Qualcomm are great cover actions to see. Take a deep breath, get ready, the New Year is just around the corner, and while we're all ready to celebrate, just in principle, because leaving 2020 is reason enough for joy, let's also take stock of where we are and where we're headed. There is a growing sense of optimism, begeted by the availability of COVID vaccines and the potential they give for a return to normality on major streets across the country. Finally, a possibility that the lockdown and social estating schemes will really end, and in the short term. There is a real possibility that, by the end of 2021, John Q. Public may be getting back on its feet.Combine that with the current boiling of Wall Street, such as trading stock markets at or near their high levels of all time, and we are looking at the prospect of a flag year. A return to normal grass roots will be great, but we also have the prospect of a generally increasing market. Writing from JPMorgan, us chief U.S. capital strata Dubravko Lakos-Bujas writes: Equity faces one of the best backdrops in years. Risks related to global trade tensions, political uncertainty and the pandemic will disappear. At the same time, liquidity conditions remain extremely favorable, and there is an extremely favorable interest rate environment. That's a Goldilocks environment for risky assets. Lakos-Bujas does not shy away from quantifying his optimism. It is forecasting up to 19% profit for the S&P 500, saying the index will reach 4,000 in the first part of 2021 and reach up to 4,400 in the latter part of the year. Turning Lakos-Bujas' perspectives into concrete recommendations, JPM's stock analyst chart is hitting the table on three stocks that seem especially attractive. We went through the trio through the TipRanks database to see what other Wall Street analysts have to say. Sotera Health (SHC)Sotera Health occupies a unique niche in the healthcare industry, offering, through its subsidiaries, a range of security-oriented support businesses for healthcare providers. These services include sterilization procedures, laboratory testing and counseling services, and their importance is immediately clear. Sotera has more than 5,800 health care provider customers in more than 50 countries around the world. Although not a new company, two of its branches have been in business since the 1930s and 1940s - Sotera is new to stock markets, having had its IBRO on the stock exchange last November. The initial offer was considered successful, raising \$1.2 billion in a sale of 53.6 million shares. Earlier this month, Sotera announced that it was using much of the IPO's capital to pay \$1.1 billion in existing debt. This included \$341 million in a term loan, plus the \$770 million in main aggregate in a high-level note issue. The move allowed Sotera to increase its revolving credit facility to \$347.5 million. That facility is not drawn. Among the bulls is JPM analyst Tycho Peterson who rates SHC as an overweight (i.e. buy) along with a one-year price target of \$35. This figure suggests a 31% rise in current levels. (To view Peterson's path, click here) SHC is uniquely positioned to benefit from healthy growth in the end market and favorable price dynamics, Peterson said. Given a diversified operating platform, multi-year sticky contracts, an efficient pricing strategy, significant barriers to entry, and high regulatory oversight, we project 9% sales growth, with increased utilization that drives continuous expansion [and] robust FCF supports continuous deleveraging, which gives us positive in both the short and long-term prospects. Wall Street's corps of analysts is firmly behind Peterson in this case - in fact, the 7 recent reviews are unanimous purchases, making the analyst consensus a strong buy. SHC is currently trading for \$26.75, and its average price target of \$32.50 implies a 21.5% advantage by the end of 2021. (See SHC share analysis in TipRanks) Myovant Sciences (MYOV)We will continue with the health care industry, and look at Myovant Sciences. This biopharmaceutical clinical research company focuses on the main problems of reproductive system disease in both men and women. Specifically, Myovant is working to develop treatments for uterine fibroids, endometriosis, and prostate cancer. The Myovant pipeline currently has Relugolix as a treatment for fibroids and endometriosis. The drug is in phase 3 trial for the second, and has had its NDA presented for the first. It is also in process, and related to reproductive health, MVT-602, a new drug designed to improve egg maturation and aid in vitro fertilization. In addition, Myovant has announced this month that Relugolix has been approved by the FDA – under the brand name Orgovyx – as a treatment for advanced prostate cancer. The drug is the first, and currently only, oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the disease. Orgovyx is expected to enter the market in January 2021.Analyst Eric Joseph, in his note on this action for

